Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

248 11 Hybrid Cell Vaccination for Cancer Immune Therapy
geneic melanomas. Cancer Res 1990;
50: 492±8.
114 Crowley NJ, Darrow TL, Seigler HF.
Generation of autologous tumor-specific
cytotoxic T-cells using HLA-A region
matched allogeneic melanoma. Curr
Surg 1989; 46: 393±6.
115 Mitchell MS. Perspective on allogeneic
melanoma lysates in active specific
immunotherapy. Semin Oncol
1998; 25: 623±35.
116 Fujiwara H, Aoki H,Yoshioka T, Tomita
S, Ikegami R, Hamaoka T. Establishment
of a tumor-specific immunotherapy
model utilizing TNP-reactive
helper T cell activity and its application
to the autochthonous tumor system.
J Immunol 1984; 133: 509±14.
117 Berd D, Kairys J, Dunton C, Mastrangelo
MJ, Sato T, Maguire HC Jr.
Autologous, hapten-modified vaccine as
a treatment for human cancers. Semin
Oncol 1998; 25: 646±53.
118 Berd D, Maguire HC Jr, Schuchter
LM, Hamilton R, Hauck WW,
Sato T, Mastrangelo MJ. Autologous
hapten-modified melanoma vaccine as
postsurgical adjuvant treatment after
resection of nodal metastases. J Clin
Oncol 1997; 15: 2359±70.
119 Berd D, Murphy G, Maguire HC Jr,
Mastrangelo MJ. Immunization with
haptenized, autologous tumor cells induces
inflammation of human melanoma
metastases. Cancer Res 1991; 51:
2731±4.
120 Baskar S, Nabavi N, Glimcher LH,
Ostrand-Rosenberg S. Tumor cells expressing
major histocompatibility complex
class II and B7 activation molecules
stimulate potent tumor-specific
immunity. J Immunother 1993; 14: 209±
15.
121 Dranoff G, Jaffee E, Lazenby A, Golumbek
P, Levitsky H, Brose K, Jackson
V, Hamada H, Pardoll D, Mulligan
RC. Vaccination with irradiated tumor
cells engineered to secrete murine
granulocyte-macrophage colony-stimulating
factor stimulates potent, specific,
and long-lasting anti-tumor immunity.
Proc Natl Acad Sci USA 1993; 90: 3539±
43.
122 Dranoff G, Soiffer R, Lynch T,
Mihm M, Jung K, Kolesar K,
Liebster L, Lam P, Duda R, Mentzer S,
Singer S, Tanabe K, Johnson R, Sober
A, Bhan A, Clift S, Cohen L,
Parry G, Rokovich J, Richards L,
Drayer J, Berns A, Mulligan RC.
A phase I study of vaccination with
autologous, irradiated melanoma cells
engineered to secrete human granulocyte-macrophage
colony stimulating
factor. Hum Gene Ther 1997; 8: 111±23.
123 Soiffer R, Lynch T, Mihm M, Jung K,
Rhuda C, Schmollinger JC, Hodi FS,
Liebster L, Lam P, Mentzer S,
Singer S, Tanabe KK, Cosimi AB,
Duda R, Sober A, Bhan A, Daley J,
Neuberg D, Parry G, Rokovich J,
Richards L, Drayer J, Berns A,
Clift S, Dranoff G, Cohen LK, Mulligan
RC. Vaccination with irradiated
autologous melanoma cells engineered
to secrete human granulocyte-macrophage
colony-stimulating factor generates
potent antitumor immunity in patients
with metastatic melanoma. Proc
Natl Acad Sci USA 1998; 95: 13141±6.
124 Mach N, Gillessen S,Wilson SB,
Sheehan C, Mihm M, Dranoff G.
Differences in dendritic cells stimulated
in vivo by tumors engineered to secrete
granulocyte-macrophage colonystimulating
factor or Flt3-ligand. Cancer
Res 2000; 60: 3239±46.
125 Abdel-Wahab Z,Weltz C, Hester D,
Pickett N,Vervaert C, Barber JR,
Jolly D, Seigler HF. A Phase I clinical
trial of immunotherapy with interferongamma
gene-modified autologous melanoma
cells: monitoring the humoral
immune response. Cancer 1997; 80:
401±12.
126 Nemunaitis J, Bohart C, Fong T,
Meyer W, Edelman G, Paulson RS,
Orr D, Jain V, O'Brien J, Kuhn J, Kowal
KJ, Burkeholder S, Bruce J, Ognoskie
N,Wynne D, Martineau D,
Ando D. Phase I trial of retroviral vectormediated
interferon (IFN)-gamma gene
transfer into autologous tumor cells in
patients with metastatic melanoma.
Cancer Gene Ther 1998; 5: 292±300.
127 Dranoff G, Jaffee E, Lazenby A, Golumbek
P, Levitsky H, Brose K, Jack-